Adrenalectomy is the sole curative therapy and the current gold standard of care for patients with pheochromocytoma. Historically, nearly 50% of patients with pheochromocytoma were obese but with increasing rates of obesity these rates continue to increase substantially. Studies evaluating the safety of adrenalectomy for pheochromocytoma remain limited with the largest of eight previous studies including only 177 patients and all other studies having < 100 patients with obesity
1. Furthermore, studies evaluating a retroperitoneal approach in patients with obesity were limited to 41 and 141 obese patients, respectively
2,3. Considering this, understanding the impact of obesity on outcomes following adrenalectomy for pheochromocytoma is needed and becoming increasingly important from a patient selection and counseling perspective and from a quality improvement viewpoint. …